stockrowPraxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
Follow PRAX
Alert me
Praxis Precision Medicines, Inc. (PRAX) EBITDA
Praxis Precision Medicines, Inc.'s EBITDA for fiscal 2025 was −$329.7M, compared with −$204.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$380.8M. Over the past ten years it has ranged from −$329.7M (fiscal 2025) to −$22.7M (fiscal 2018) — the current reading is the lowest in ten years. Praxis Precision Medicines, Inc. ranks 561st of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$329.7M | — |
| FY2024 | −$204.8M | — |
| FY2023 | −$125.9M | — |
| FY2022 | −$213.6M | — |
| FY2021 | −$165.1M | — |
| FY2020 | −$61.9M | — |
| FY2019 | −$35.8M | — |
| FY2018 | −$22.7M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$97.6M | — |
| Mar 2026 | −$106.5M | — |
| Dec 2025 | −$97.7M | — |
| Sep 2025 | −$79.0M | — |
| 23 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $234.3M |
| CORT Corcept Therapeutics Incorporated compare | $108.8M |
| AXSM Axsome Therapeutics, Inc. compare | −$139.8M |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −$186.2M |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$204.6M |
| SYRE Spyre Therapeutics, Inc. compare | −$250.2M |
| ABVX Abivax SA Sponsored ADR compare | −$338.0M |
| PRAX Praxis Precision Medicines, Inc. | −$380.8M |
| CYTK Cytokinetics, Incorporated compare | −$694.7M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item